newsfilter
← Latest News
PR Newswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • On October 13, 2025, Tvardi shares fell over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis.
  • The study aimed to assess safety, pharmacokinetics, & exploratory lung function outcomes, including changes in Forced Vital Capacity (FVC).
  • Tvardi concluded the study did not meet its goals based on preliminary safety data & efficacy results showing the placebo group had lower percent predicted FVC than treatment arms.
  • Senior Partner James (Josh) Wilson invites investors with significant losses to contact him at 877-247-4292 or 212-983-9330 (Ext. 1310).
  • Additional information is available at www.faruqilaw.com/TVRD or www.faruqilaw.com.
  • The firm maintains offices in New York, Pennsylvania, California, & Georgia & has recovered hundreds of millions for investors since 1995.
  • Communications with the firm are confidential, & prior results do not guarantee future outcomes.